Amgen and Allergan’s Phase III study of biosimilar candidate ABP 215 met its primary and secondary endpoints in patients with advanced non-squamous non-small cell lung cancer (NSCLC). The study evaluated the efficacy and safety of ABP 215 compared with Genentech’s Avastin (bevacizumab). The primary endpoint, an assessment of objective response rates (ORR), showed clinical equivalence. Safety and immunogenicity of ABP 215 were comparable to bevacizumab. Secondary endpoint results were consist...